Advanced searches left 3/3

Metastatic Uveal Melanoma - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 February 2022

* If you want to update the article please login/register

A Pilot Study of Hepatic Irradiation with Yttrium90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.

In metastatic uveal melanoma, the primary aim of this research was to determine the safety and tolerability of sequential yttrium 90 resin microspheres and immunotherapy with ipilimumab and nivolumab. Materials and Methods: Twenty-six patients with uveal melanoma with hepatic metastases were accepted into a pilot study. Results: Initial dosing of both yttrium 90 and immunotherapy resulted in significant toxicity, which led to increased toxicity. With lowering the dose of yttrium 90 to limit the normal liver dose to 35Gy and lowering the ipilimumab dose to 1 mg/kg, the toxicities were tolerable, with no apparent change in efficacy. Conclusions: With dose cuts, sequential therapy with yttrium 90 and immunotherapy with ipilimumab and nivolumab is safe and tolerable, and it has involvement in metastatic uveal melanoma. These findings support a controlled trial's findings, showing that yttrium 90 resin microsphere microspheres contribute to the use of combination immunotherapy in this disease.

Source link: https://europepmc.org/article/MED/35021863


Metastatic uveal melanoma: The final frontier.

Primary intraocular melanoma treatment has progressed, its source genes are mostly unknown, and the ways to determine its risk of metastases are very specific, based on an international staging system and genetic information. Metastases are the most common cause of death after uveal melanoma is identified, but no agreement has been reached on surveillance, diagnosis, or treatment of disseminated disease has been achieved, and survival has not improved until recently. Metastatic uveal melanoma studies are small, uncontrolled, retrospective, and do not specify staging. These drugs now work on selected patients and provide 6 months longer median overall survival as compared to conventional chemotherapy and, most recently, tebentafusp as first-line treatment in a large meta-analysis.

Source link: https://europepmc.org/article/MED/34999237


Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.

Patients with hepatic-dominant metastatic uveal melanoma treated with PHP were assessed for their safety, adaptation to therapy, and survival. This two-center study was intended to investigate the risks, response to therapy, and survival of patients with hepatic-dominant metastatic uveal melanoma treated with PHP. According to RECIST1. 1, a total of 66 patients with liver-dominant metastasize uveal melanoma, who were treated with 145 PHP between April 2014 and May 2020 were retrospectively evaluated with regard to adverse events, response, and disease prevention, as well as progression-free and overall survival. Following the introduction of PHP, median hepatic PFS was 12. 4 months, and median OS was 18. 4 months.

Source link: https://europepmc.org/article/MED/35008282


Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?

In comparison to the dramatic benefits of immunotherapy in several tumor types, as seen in cutaneous melanoma, immune checkpoint inhibitors in Metastatic UM did not achieve comparable results in Metastatic UM. This multi-center study, involving n = 45 patients with MUM, compared the results of combining ICI with liver-directed therapy with respect to standard therapies on overall survival. Our findings showed a significant survival difference between Cohort 1 and Cohort 2, suggesting that this combination may increase the efficacy of immunotherapy and provide a survival benefit.

Source link: https://europepmc.org/article/MED/34945010


Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma.

Adult melanoma is the most common primary ocular malignancy, distinguished by gene mutations in G protein subunit alpha q and G protein subunit alpha 11; Uveal melanoma is the most common primary ocular malignancy in adults, with gene mutations in G protein subunit alpha q and subunit alpha 11. Metastatic lesions from 87 MUM patients were studied by next-generation sequencing. Most GNA11 mutations were Q209L and Q209P, however GNAQ mutations constituted Q209L and Q209P. Interestingly, Met-to-Death was longer in patients with GNAQ/GNA11 Q209L mutations than GNAQ/GNA11 Q209L mutations, suggesting that the difference in mutation type in GNAQ/GNA11 may influence MUM prognosis.

Source link: https://europepmc.org/article/MED/34830903

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions